Zynerba is conducting clinical studies of ZYN002 in a number in patients with a number of neuropsychiatric conditions the United States and Australia/New Zealand. ZYN002 is an experimental treatment. This means that it is not approved by government regulatory bodies, including the United States Food and Drug Administration (FDA) and other agencies and must be tested to see if it is an effective and safe treatment.
The following clinical studies are active and currently enrolling patients in the U.S.
- CONNECT-FX (Clinical Study of Cannabidiol (CBD) in Children and Adolescents with Fragile X)